Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SPD465-304 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2006-11-07 |
26% |
| SPD465-303 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2005-11-04 |
26% |
| SPD465-301 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2005-06-14 |
26% |